Table 2

Platelet-rich plasma and control injection protocols

StudyPRP
type*		Number of
injections		Injection contents and volume†
PRPControl
Behera et al134B13 mL PRP, 0.5 mL calcium chloride3 mL bupivacaine, 0.5 mL normal saline
de Jonge et al141A14 mL PRP4 mL normal saline
Dragoo et al151A13 mL bupivacaine → 6 mL PRP3 mL bupivacaine
Gautam et al163B12 mL PRP2 mL methylprednisolone
Gosens et al171A13 mL PRP3 mL triamcinolone
Kesikburun et al181A11 mL lidocaine → 5 mL PRP1 mL lidocaine → 5 mL normal saline
Krogh et al191A110–15 mL lidocaine → 3 mL PRP10–15 mL lidocaine → 3 mL normal saline
Krogh et al401A110–15 mL lidocaine → 3 mL PRP10–15 mL lidocaine → 1 mL triamcinolone, 2 mL lidocaine
Krogh et al201A110–15 mL lidocaine → 6 mL PRP10–15 mL lidocaine → 6 mL normal saline
Lebiedziński et al213B13 mL PRP1 mL betamethasone, 2 mL lignocaine
Mishra et al221A1Bupivacaine‡ → 2–3 mL PRPBupivacaine‡ → 2–3 mL bupivacaine
Montalvan et al233B2§2 mL lidocaine → 2 mL PRP2 mL lidocaine → 2 mL normal saline
Palacio et al243B13 mL PRP3 mL neocaine
Palacio et al243B13 mL PRP3 mL dexamethasone
Rha et al251A2§<1 mL lidocaine → 3 mL PRP<1 mL lidocaine
Shams et al263B12–2.5 mL PRP5 mL triamcinolone
Stenhouse et al273B2§1–2 mL lignocaine → 2 mL PRP1–2 mL lignocaine
Yadav et al28#A¶11 mL PRP1 mL methylprednisolone

  • *From Mishra et al41 (1A=high platelet concentration with leucocyte counts > whole blood and no exogenous platelet activation, 3B=low platelet concentration with leucocyte counts < whole blood and no exogenous platelet activation, 4B=3B but with exogenous platelet activation).

  • †‘→’ implies sequential injection.

  • ‡Volume unspecified.

  • §Injections separated by 4-week interval.

  • ¶Leucocyte concentration and activation method unknown.

  • PRP, platelet-rich plasma.